Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 28 2023 - 8:00AM
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage
biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced that Philip
Astley-Sparke, Chief Executive Officer of Replimune, will present
at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,
January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in
San Francisco, CA.
A simultaneous webcast will be available in the
Investors section of Replimune’s website at www.replimune.com. A
replay will be available for 30 days following the conference.
About Replimune Replimune
Group, Inc., headquartered in Woburn, MA, was founded in 2015
with the mission to transform cancer treatment by pioneering the
development of a novel portfolio of oncolytic immunotherapies.
Replimune’s proprietary RPx platform is based on a potent HSV-1
backbone intended to maximize immunogenic cell death and the
induction of a systemic anti-tumor immune response. The RPx
platform is designed to have a unique dual local and systemic
activity consisting of direct selective virus-mediated killing of
the tumor resulting in the release of tumor derived antigens and
altering of the tumor microenvironment to ignite a strong and
durable systemic response. The RPx product candidates are expected
to be synergistic with most established and experimental cancer
treatment modalities, leading to the versatility to be developed
alone or combined with a variety of other treatment options. For
more information, please visit www.replimune.com.
Investor InquiriesChris BrinzeyICR
Westwicke339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen
GoldenbergReplimune917.548.1582media@replimune.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2024 to May 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From May 2023 to May 2024